OBJECTIVE: Penile metastases are late manifestations of a primary tumor, and they are a sign of poor prognosis. We report a case of a rare presentation: penile metastases from prostate cancer. METHODS: 77 year-old male presented hematuria and acute urinary retention; on physical examination multiple hard lesions were detected. The patient underwent a Doppler ultrasound, subsequent penile and prostate biopsy, and staging study. Currently he is being treated with complete androgen blockade. RESULTS: A histological study of the penile biopsy showed penile metastasis from prostate adenocarcinoma. The histological study of prostate biopsy confirmed Gleason 8 (4+4) adenocarcinoma. CONCLUSIONS: Despite of the different therapeutic alternatives for treatment of symptomatic penile metastases, it would be with palliative target; due to the median survival of these patients is less than a year.
OBJECTIVE:Penile metastases are late manifestations of a primary tumor, and they are a sign of poor prognosis. We report a case of a rare presentation: penile metastases from prostate cancer. METHODS: 77 year-old male presented hematuria and acute urinary retention; on physical examination multiple hard lesions were detected. The patient underwent a Doppler ultrasound, subsequent penile and prostate biopsy, and staging study. Currently he is being treated with complete androgen blockade. RESULTS: A histological study of the penile biopsy showed penile metastasis from prostate adenocarcinoma. The histological study of prostate biopsy confirmed Gleason 8 (4+4) adenocarcinoma. CONCLUSIONS: Despite of the different therapeutic alternatives for treatment of symptomatic penile metastases, it would be with palliative target; due to the median survival of these patients is less than a year.
Authors: Ke Zhang; Jun Da; Hai-Jun Yao; Da-Chao Zheng; Zhi-Kang Cai; Yue-Qing Jiang; Ming-Xi Xu; Zhong Wang Journal: Medicine (Baltimore) Date: 2015-01 Impact factor: 1.889
Authors: Andrea Cocci; Oliver W Hakenberg; Tommaso Cai; Gabriella Nesi; Lorenzo Livi; Beatrice Detti; Andrea Minervini; Girolamo Morelli; Marco Carini; Sergio Serni; Mauro Gacci Journal: Oncotarget Date: 2017-12-18